Jazz Pharmaceuticals has claimed FDA approval for its HER2-directed bispecific antibody Ziihera as a treatment for biliary tract cancer (BTC), the first in a series of potential indications that the ...

US FDA approves Jazz Pharma’s Ziihera to treat adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer: Dublin Friday, November 22, 2024, 1 ...

“You’re throwing the best treatments you have at them and things aren’t working, and that is a very awful experience for our patients. It’s a humbling experience for us,” Mizrahi said. He estimates ...

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

Ziihera is the first dual HER2-targeted bispecific antibody approved in the U.S. for HER2-positive biliary tract cancer ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved ...

The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for ...

The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost ...

Jazz Pharmaceuticals says the U.S. Food and Drug Administration has approved use of the tumor-fighting antibody to treat adults with a form of biliary-tract cancer (BTC) ...

The agency has approved Ziihera for adults with previously treated, unresectable or metastatic HER2-positive biliary tract ...

US equity futures were cautiously higher ahead of Thursday's opening bell as traders digested earnings and guidance from artificial intelligence chipmaker Nvidia (NVDA). Dow Jones Industrial Average ...